Triptans and SSRIs
Isolated cases of serotonin syndrome have been reported in patients using triptans and SNRIs or SSRIs.
In 2006, the FDA issued a warning of possible serotonin syndrome in patients receiving triptans together with either selective serotonin/norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs).1 Despite periodic reports providing evidence that the combination is not dangerous, the warning persists in the triptan labeling. Given that about 1/4 of patients on triptans receive SNRIs or SSRIs, it probably contributes substantially to “alert fatigue” for pharmacists. New evidence has appeared regarding the clinical importance of this interaction.
REASON FOR THE WARNING
Isolated cases of serotonin syndrome have been reported in patients using triptans and SNRIs or SSRIs,2-4 and the FDA apparently has received additional reports. It was not clear, however, that all the patients actually had serotonin syndrome, and it is possible that the reactions were caused by the SNRI or SSRI alone or by some other serotonergic drug given concurrently with it. The evidence in support of serotonin syndrome from triptans plus SNRIs or SSRIs, therefore, is meager.
A 14-year electronic health records study looked at data from 19,017 patients who had concurrently received a triptan and an SNRI or SSRI.5 Just 2 patients were classified as having definite serotonin syndrome. These data are consistent with previous clinical and pharmacokinetic studies that failed to observe serotonin syndrome in more than 2000 patients receiving triptans and SSRIs.6-10 Although we cannot rule out the possibility that isolated patients on the combination may develop serotonin syndrome, the risk appears to be extraordinarily low. Indeed, the risk may be similar to the extremely small risk of sero- tonin syndrome from the use of SSRIs alone.5
In addition, from a theoretical standpoint, triptans should not interact with SNRIs or SSRIs to produce serotonin syndrome. The condition is thought to be mediated by 5HT2A receptors and possibly 5HT1A, yet the affinity of triptans is primarily for 5HT1B and 5HT1D receptors. Pharmacokinetic interactions are possible because frovatriptan and zolmitriptan are metabolized by CYP1A2, and fluvoxamine is a potent inhibitor of CYP1A2. Although this would not result in serotonin toxicity, it would be prudent to avoid these triptans in patients receiving fluvoxamine.
Given the compelling evidence for an extremely low risk of serotonin syndrome in patients using triptans with SNRIs or SSRIs, it does not appear clinically necessary to warn prescribers about these interactions. Nonetheless, as long as the warnings remain on the triptan labels, it presents a dilemma for pharmacists. If, for example, the patient on a triptan and SSRI took some third drug with serotonergic effects, such as tramadol, the interaction between the SSRI and the tramadol might produce actual serotonin syndrome, and the triptan-SSRI combination might be falsely blamed for the adverse effect. An alternative to ignoring the interaction might be to advise the patient that the interaction is mentioned on the label but not generally considered to be clinically important. The patient also could be advised to be alert for symptoms of serotonin syndrome, especially the characteristic neuromuscular effects such as myoclonus, rigidity, and tremors. That would be useful even for patients on SNRIs or SSRIs because the syndrome occasionally occurs with the addition of other serotonergic agents.
Although isolated cases of serotonin syndrome have been reported with combined use of triptans with SNRIs or SSRIs, it is not clear that these cases represent an actual drug interaction.
Epidemiologic and pharmacokinetic studies suggest that the risk of serotonin syndrome from combining triptans with SNRIs or SSRIs is extraordinarily low and may be no higher than the use of SNRIs or SSRIs alone.
Given that the triptan labels warn of possible serotonin syndrome if SNRIs or SSRIs are used concurrently, there may be medicolegal considerations if the patient develops serotonin syndrome for whatever reason. Warning the patient about the signs and symptoms of serotonin syndrome is useful.
John R. Horn, PharmD, FCCP, and Philip D. Hansten, PharmD, are both professors of pharmacy at the University of Washington School of Pharmacy in Seattle. For an electronic version of this article, including the online table, visit hanstenandhorn.com.
- FDA. Public health advisory - combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. FDA website. wayback.archive- it.org/7993/20170406044820/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSaf etyInformationforPatientsandProviders/ucm124349.htm Updated August 16, 2013. Accessed April 11, 2018.
- Hendrix Y, van Zagten MS. Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan. Ned Tijdschr Geneeskd. 2005;149(16):888-890.
- Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996;16(5):323-327. doi: 10.1046/j.1468- 2982.1996.1605323.x.
- Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother. 1998;32(1):33-38. doi: 10.1345/aph.17204.
- Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome [published online February 26, 2018]. JAMA Neurol. 2018. doi:10.1001/jamaneurol.2017.5144. 4
- Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003;2(2):123-132. doi: 10.1517/14740322.214.171.124.
- Putnam GP, O’Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale prospective study. Cephalalgia. 1999;19(7):668-675. doi: 10.1046/j.1468-2982.1999.019007668.x.
- Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache. 2003;43(9):962-974.
- Smith DA, Cleary EW, Watkins S, Huffman CS, Polvino WJ. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther. 1998;36(6):301-305.
- Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol. 1999;39(2):192-199.